Real-World Effectiveness Study of Benralizumab for Severe Eosinophilic Asthma: ZEPHYR 2

Donna Carstens, Diego J. Maselli, Fan Mu, Erin E. Cook, Danni Yang, Joshua A. Young, Keith A. Betts, Eduardo Genofre, Yen Chung

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Background: Benralizumab is an mAb therapy for severe eosinophilic asthma. Real-world data on its clinical impact in various patient populations such as patients with varying eosinophil levels, previous biologic use, and extended follow-up in the United States are limited. Objective: To determine the effectiveness of benralizumab in different asthmatic patient cohorts and its long-term clinical impact. Methods: Patients with asthma treated with benralizumab from November 2017 to June 2019 with 2 or more exacerbations in the 12 months before benralizumab initiation (index) were included in this pre-post cohort study that used medical, laboratory, and pharmacy US insurance claims. Asthma exacerbation rates in the 12 months pre and post index were compared. Nonmutually exclusive patient cohorts were defined by blood eosinophil counts (<150, ≥150, 150-<300, <300, and ≥300 cells/μL), a switch from another biologic, or follow-up for 18 or 24 months post index. Results: There were 429 patients in the eosinophil cohort, 349 in the biologic-experienced cohort, and 419 in the extended follow-up cohort. In all eosinophil cohort subgroups, the asthma exacerbation rate decreased from 3.10-3.55 per patient-year (PPY) pre index to 1.11-1.72 PPY post index (52%-64% decrease; P < .001). Similar decreases were observed in patients switching from omalizumab (3.25 to 1.25 PPY [62%]) or mepolizumab (3.81 to 1.78 PPY [53%]) to benralizumab and those followed up for 18 months (3.38 to 1.18 PPY [65%]) or 24 months (3.38 to 1.08 PPY [68%]) (all P < .001). In the extended follow-up cohort, 39% and 49% had no exacerbations in the 0 to 12 months and the 12 to 24 months post index, respectively. Conclusions: Benralizumab achieved significantly improved asthma control in real-world patients with different blood eosinophil counts, including eosinophil counts ranging from less than 150 to greater than or equal to 300 cells/μL, switching from other biologics, or treated for up to 24 months.

Original languageEnglish (US)
Pages (from-to)2150-2161.e4
JournalJournal of Allergy and Clinical Immunology: In Practice
Issue number7
StatePublished - Jul 2023


  • Benralizumab
  • Exacerbation
  • Real-world study
  • Severe eosinophilic asthma

ASJC Scopus subject areas

  • Immunology and Allergy


Dive into the research topics of 'Real-World Effectiveness Study of Benralizumab for Severe Eosinophilic Asthma: ZEPHYR 2'. Together they form a unique fingerprint.

Cite this